[letters] government fully considered hpv vaccine
(Source: BMJ)...
POSTED 11/18/2008 at 11:00 PM --
|
[letters] all data on both vaccines must be considered
(Source: BMJ)...
POSTED 11/18/2008 at 11:00 PM --
|
Cervical screening programme 2007/08
This bulletin presents information about the cervical... (Source: Cancer Plan Newsfeed)...
POSTED 11/18/2008 at 10:07 PM --
|
Sarah boseley: where lives are cheap
Thousands of 12- and 13-year-old girls will be lining up outside their school medical offices this term, some of them shivering, stomachs lurching, waiting for a jab in the arm that it is hoped will prevent them suffering cervical cancer - a particularly unpleasant form of the disease which kills more than 900 women a year in the UK.There is every sign that takeup of the vaccine will not be universal. In a pilot study, 20% of parents did not give permission for their daughter to have the jab - whether from apathy or anxiety. Girls are being told that if they feel strongly, they can go to their GP and get vaccinated anyway, but that will surely be rare. And takeup will certainly slump for the boosters, months later.In spite of a health service information campaign and assiduous marketing by......
POSTED 11/18/2008 at 06:18 PM --
|
Re: cost-effectiveness of cervical cancer screening with human papillomavirus dna testing and hpv-16,18 vaccination
(Source: JNCI)...
POSTED 11/17/2008 at 11:00 PM --
|
South african advocacy group calls for increased hpv vaccinations of hiv-positive women
The Treatment Action Campaign of South Africa is calling on pharmaceutical companies to "dramatically lower the prices" of human papillomavirus vaccines to make them more affordable for HIV-positive women, the Cape Times/IOL reports. According to TAC, HIV-positive women are 10 times more likely than women who are HIV-negative to contract a strain of HPV that causes cervical cancer. (Source: Health News from Medical News Today)...
POSTED 11/17/2008 at 12:00 PM --
|
Vaccine for skin cancer 'available in five years'
The scientist who developed a vaccine for cervical cancer is working on another inoculation against certain types of skin cancer that could be available in five years time. (Source: Telegraph Health)...
POSTED 11/17/2008 at 07:14 AM --
|
Aussie scientist to unveil skin cancer vaccine
The pioneering Australian scientist who discovered the cure for cervical cancer is on the verge of creating the world's first vaccine for skin cancer. (Source: FOXNews.com)...
POSTED 11/17/2008 at 07:00 AM --
|
New data on cancer diagnostic presented by arbor vita
Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, presented new data on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer. Targeted for use throughout the developing world, this diagnostic test is being developed in partnership with PATH. (Source: Medical Devices News From Medical News Today)...
POSTED 11/17/2008 at 03:00 AM --
|
Knowledge and beliefs related to cervical cancer and screening among korean american women
The purpose of this article is to examine knowledge and health beliefs associated with cervical cancer screening among Korean American women. A telephone survey was conducted with 189 Korean American women in the Chicago area. Age, marital status, income, knowledge of early detection method for cervical cancer, and perceived beliefs about benefits of and barriers to receiving Pap tests were all related to outcomes of ever having a Pap test and having had one in the preceding 3 years. Variables uniquely related to ever having a Pap test were education, employment status, fluency in English, and proportion of life spent in the United States. Variables uniquely related to having had the test during the preceding 3 years were having a usual source of care and regular checkups. Different interv......
POSTED 11/16/2008 at 11:00 PM --
|
A single-codon mutation converts hpv16 e6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of hpv-positive hela cervical cancer cells
A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells
Oncogene advance online publication, November 17, 2008. doi:10.1038/onc.2008.422
Authors: T Ristriani, S Fournane, G Orfanoudakis, G Travé
& M Masson (Source: Oncogene)...
POSTED 11/16/2008 at 11:00 PM --
|
Health-africa: cervical cancer strikes poor women hardest
CAPE TOWN, Nov 15 (IPS) - Of the 490,000 women worldwide who are diagnosed
with cervical cancer each year, 80 percent live in the developing
world. Every year, 55,000 women in sub-Saharan Africa alone
develop this disease, which is ten times more likely to affect
women living with HIV. (Source: IPS Inter Press Service - HIV/AIDS)...
POSTED 11/16/2008 at 10:16 PM --
|
Gardasil(r) demonstrated efficacy in preventing hpv-related disease in males in phase iii study
GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV) types 6, 11, 16 and 18 in a pivotal Phase III study in men aged 16 to 26. (Source: Health News from Medical News Today)...
POSTED 11/16/2008 at 02:00 AM --
|
Africa: cervical cancer strikes poor women hardest
Of the 490,000 women worldwide who are diagnosed with cervical cancer each year, 80 percent live in the developing world. Every year, 55,000 women in sub-Saharan Africa alone develop this disease, which is ten times more likely to affect women living with this virus. (Source: AllAfrica News: Health and Medicine)...
POSTED 11/15/2008 at 03:44 PM --
|
Researchers say identification of women with hpv types 16, 18 and 45 could improve early intervention to stop cervical cancer
As testing for high-risk types of the human papillomavirus (HPV) emerges as the gold standard in cervical cancer prevention, scientists are already researching how to determine even more precisely who is most likely to develop the disease and thus are in need of more immediate intervention. (Source: Health News from Medical News Today)...
POSTED 11/15/2008 at 02:00 AM --
|
A phase i/ii study of extended field radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in patients with cervical carcinoma metastatic to the para-aortic lymph nodes: a gynecologic oncology group study.
CONCLUSIONS: Paclitaxel and cisplatin combination chemotherapy concurrent with extended field pelvic para-aortic irradiation can be administered at the described MTD and shows a higher than previously reported disease-free survival in relation to historical data. The 56% survival to date, and 50% estimated 48 month survival, warrants validation in a larger prospective cohort. Central radiation dose reduction is being considered in the next trial to decrease late toxicity of regimen.
PMID: 19010522 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)...
POSTED 11/14/2008 at 11:00 PM --
|
Monoclonal antibody cc188 binds a carbohydrate epitope expressed on the surface of both colorectal cancer stem cells and their differentiated progeny.
CONCLUSION: mAb CC188 selectively targets a carbohydrate epitope expressed on cancer cells, providing a viable method for specific tumor imaging and targeted therapy.
PMID: 19010863 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)...
POSTED 11/14/2008 at 11:00 PM --
|
Study finds hpv vaccine gardasil effective at preventing male genital lesions
Merck's human papillomavirus vaccine Gardasil is about 90% effective in preventing external lesions -- mostly gential warts -- caused by the four HPV strains it targets and 45% effective in preventing HPV infection, according to a Merck-funded study, Reuters reports (Fox, Reuters, 11/12). (Source: Health News from Medical News Today)...
POSTED 11/14/2008 at 09:00 AM --
|
Modelling research shows cervarixtm-induced immune response may be prolonged for at least 20 years for both hpv 16 and 18
Results of three statistical models presented today at the European Research Organisation on Genital Infection and Neoplasia (EUROGIN) annual meeting in Nice, France, suggest that young women vaccinated with GlaxoSmithKline's cervical cancer vaccine CervarixTM could look forward to a prolonged immune (Source: Health News from Medical News Today)...
POSTED 11/14/2008 at 07:00 AM --
|
Arbor vita corporation: arbor vita presents new data on cancer diagnostic at eurogin
NICE, FRANCE (MARKET WIRE) Arbor Vita Corporation (AVC), a privately held biopharmaceutical company, presented new data today on its rapid, point-of-care prototype HPV test with a high positive predictive value for cervical cancer and pre-cancer. Targeted for use throughout the developing world, this diagnostic test is being developed in partnership with PATH. The presentation, "Development of a Rapid Diagnostic Test for Cervical Pre-Cancer and Cancer," was given during the "Molecular Markers" session at Eurogin 2008, an international conference providing a comprehensive overview of current scientific advances in the (Source: Market Wire - Pharmaceuticals and Biotech)...
POSTED 11/14/2008 at 07:00 AM --
|
